ContractWarrant Agreement • August 10th, 2017 • Arsanis, Inc. • Biological products, (no disgnostic substances) • California
THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET FORTH IN SECTIONS 5.3 AND 5.4 BELOW, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND LAWS OR, IN THE OPINION OF LEGAL COUNSEL IN FORM AND SUBSTANCE SATISFACTORY TO THE ISSUER, SUCH OFFER, SALE, PLEDGE OR OTHER TRANSFER IS EXEMPT FROM SUCH REGISTRATION.
INDEMNIFICATION AGREEMENTIndemnification Agreement • August 10th, 2017 • Arsanis, Inc. • Biological products, (no disgnostic substances) • Delaware
THIS AGREEMENT (the “Agreement”) is made and entered into as of [ ] between Arsanis, Inc., a Delaware corporation (the “Company,” which term shall include where appropriate, any Entity (as hereinafter defined)), and [ ] (“Indemnitee”).
ARSANIS, INC. SECOND AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT Dated as of April 12, 2016Investors’ Rights Agreement • August 10th, 2017 • Arsanis, Inc. • Biological products, (no disgnostic substances) • Delaware
This Second Amended and Restated Investors’ Rights Agreement (this “Agreement”) is entered into this 12th day of April, 2016, by and among Arsanis, Inc., a Delaware corporation (the “Company”) and the individuals and entities listed on Exhibit A attached hereto (the “Investors”).
OPTION AND LICENSE AGREEMENTOption and License Agreement • August 10th, 2017 • Arsanis, Inc. • Biological products, (no disgnostic substances) • New York
THIS OPTION AND LICENSE AGREEMENT (the “Agreement”) is made effective as of February 27, 2017 (the “Effective Date”), by and between ADIMAB, LLC, a Delaware limited liability company having an address at 7 Lucent Drive, Lebanon, NH 03766 (“Adimab”), and ARSANIS INC., a Delaware corporation having an address at 890 Winter Street, Suite 230, Waltham, MA 02451-1472 (“Arsanis”).
Funding contract agreed between Österreichische Forschungsförderungsgesellschaft mbH (FFG) as funding donor and ARSANIS Biosciences GmbH Helmut-Qualtinger-Gasse 2 Company register number FN 354305m as funding recipient.Funding Contract • August 10th, 2017 • Arsanis, Inc. • Biological products, (no disgnostic substances)
LEASE AGREEMENTLease Agreement • August 10th, 2017 • Arsanis, Inc. • Biological products, (no disgnostic substances)
LOAN AND SECURITY AGREEMENTLoan and Security Agreement • August 10th, 2017 • Arsanis, Inc. • Biological products, (no disgnostic substances) • Delaware
THIS LOAN AND SECURITY AGREEMENT (this “Agreement”) dated as of December 7, 2012 (the “Effective Date”) between SILICON VALLEY BANK, a California corporation with a loan production office located at 275 Grove Street, Suite 2-200, Newton, Massachusetts 02466 (“Bank”), and ARSANIS, INC., a Delaware corporation (“Borrower”), provides the terms on which Bank shall lend to Borrower and Borrower shall repay Bank. The parties agree as follows:
Funding Contract executed between the Österreichische Forschungsförderungsgesellschaft mbH (FFG) as Funding Agency and ARSANIS Biosciences GmbH Helmut-Qualtinger-Gasse 2 Company Register No. 354305m as Funding RecipientFunding Contract • August 10th, 2017 • Arsanis, Inc. • Biological products, (no disgnostic substances)
Funding agreement concluded between Österreichische Forschungsförderungsgesellschaft mbH (FFG) as a funding entity and ARSANIS Biosciences GmbH Helmut-Qualtinger-Gasse 2 Commercial Register No.: 354305m as a recipient.Funding Agreement • August 10th, 2017 • Arsanis, Inc. • Biological products, (no disgnostic substances)
